

S.5 Long-term risks

Intervention	Outcome(s)	Population – psoriasis phenotype	Number experiencing event																							
PUVA (oral)	Skin cancer – SCC	Plaque (84%), guttate (12%) and erythrodermic (4%) psoriasis	<p>Relative risk compared with the general population</p> <p>PUVA exposures RR</p> <table> <tr> <td><100</td> <td>5.1 (3.5-7.2)</td> </tr> <tr> <td>100-159</td> <td>8.4 (5.6-12.1)</td> </tr> <tr> <td>160-336</td> <td>26.5 (22.2-31.4)</td> </tr> <tr> <td>≥337</td> <td>68.5 (54.9-84.5)</td> </tr> </table> <p>Absolute increase in risk</p> <table> <thead> <tr> <th>PUVA exposures</th> <th>SCCs</th> <th>% increase in 10-year risk</th> </tr> </thead> <tbody> <tr> <td><100</td> <td>18</td> <td>1.7%</td> </tr> <tr> <td>100-159</td> <td>15</td> <td>2.7%</td> </tr> <tr> <td>160-336</td> <td>68</td> <td>8.8 %</td> </tr> <tr> <td>≥337</td> <td>34</td> <td>12.7%</td> </tr> </tbody> </table>	<100	5.1 (3.5-7.2)	100-159	8.4 (5.6-12.1)	160-336	26.5 (22.2-31.4)	≥337	68.5 (54.9-84.5)	PUVA exposures	SCCs	% increase in 10-year risk	<100	18	1.7%	100-159	15	2.7%	160-336	68	8.8 %	≥337	34	12.7%
<100	5.1 (3.5-7.2)																									
100-159	8.4 (5.6-12.1)																									
160-336	26.5 (22.2-31.4)																									
≥337	68.5 (54.9-84.5)																									
PUVA exposures	SCCs	% increase in 10-year risk																								
<100	18	1.7%																								
100-159	15	2.7%																								
160-336	68	8.8 %																								
≥337	34	12.7%																								
NBUVB	Skin cancer	Insufficient data available																								
Methotrexate	Liver fibrosis, bone marrow suppression and pneumonitis	No long-term data available																								
Ciclosporin	Hypertension, renal impairment, gout and hyperuricaemia	No long-term data available																								
Acitretin	Hyperlipidaemia, hepatotoxicity, skeletal AEs and cheilitis	No long-term data available																								

PUVA: Psoralen plus UVA

RR: Relative risk

SCC: Squamous cell carcinoma